

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application  
 Commissioner for Patents  
 P. O. Box 1450  
 Alexandria, VA 22313-1450  
 Sir:

Atty. Dkt.: 159-84

Date: April 19, 2004

Attached for filing is the patent application of:

Inventor: NOMURA et al

Entitled: ORAL PHARMACEUTICAL COMPOSITION

and including attachments as noted below:

- ☐ Newly executed Declaration, ☒ Copy of Declaration from prior application, ☒ Abstract  
☐ Please **delete** the following inventors in the continuation/division/continuation-in-part application:

**Deleted persons:**

33 pages of specification and claims (including 11 numbered claims), and

0 sheets of accompanying drawing/s for Figures

☐ Record the attached assignment to \_\_\_\_\_, and return to the undersigned.☐ Attached is a Power of Attorney.☒ Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications:**Application Number****Country****Day/Month/Year Filed**

290341/1999

Japan

12 October 1999

PCT/JP00/07045

11 October 2000

, respectively, the entire content of which is hereby incorporated by reference in this application..

☐ Certified copy(ies) of foreign application(s) is/are attached.☒ Certified copy(ies) filed on July 19, 2001 in prior appln. no. 09/857,795 filed July 19, 2001☐ This application claims the benefit of Provisional Application No. \_\_\_\_\_, filed \_\_\_\_\_, the entire content of which is hereby incorporated by reference in this application.☒ This application is a ☒ continuation/☐ division/☐ continuation-in-part of Application No. 09/857,795, filed July 19, 2001, \_\_\_\_\_, the entire content of which is hereby incorporated by reference in this application.☒ Petition filed in prior application to extend its life to insure co-pendency.☒ The prior application is assigned to Daiichi Suntory Pharma Co., Ltd., Tokyo, Japan.☒ It is hereby requested that the Examiner consider the art cited in the parent application by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached.☐ Applicant claims "small entity" status. ☐ "Small entity" statement attached.☒ Please enter the attached preliminary amendment prior to calculation of filing fee:

☒ Also attached: ☒ Information Disclosure Statement; ☐ Non-Publication Request; ☐ Nucleotide and/or Amino Acid Sequence Submission; ☐ Statement deleting Inventor(s) named in prior application; ☐ Other:

**FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HERewith CANCELED**

Basic Filing Fee				\$	770.00
Total effective claims	9	- 20 (at least 20) =	0	x \$ 18.00	\$ 0.00
Independent claims	1	- 3 (at least 3) =	0	x \$ 86.00	\$ 0.00
If any proper multiple dependent claims now added for first time, add \$290.00 (ignore improper)				\$	0.00
				<b>SUBTOTAL</b>	\$ 770.00
If "small entity," then enter half (1/2) of subtotal and subtract				-\$	(0.00)
				<b>SECOND SUBTOTAL</b>	\$ 770.00
Assignment Recording Fee (\$40.00)				\$	0.00
				<b>TOTAL FEE ENCLOSED</b>	\$ 770.00

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**.A duplicate copy of this sheet is attached.

Correspondence Address:

**Customer Number:** 23117

Telephone: (703) 816-4000


Facsimile: (703) 816-4100

ARC:eaw

**NIXON & VANDERHYTE P.C.**

By Atty: Arthur R. Crawford, Reg. No. 25,327

Signature: \_\_\_\_\_


16834 U.S. PTO  
10/826379

041904

041904